Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy
延长半衰期的 GlyTR1 与检查点阻断相结合用于癌症免疫治疗
基本信息
- 批准号:10766646
- 负责人:
- 金额:$ 40万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-21 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibodiesAntigen TargetingAntigensB-Cell NeoplasmB-LymphocytesBindingBinding ProteinsBiological AssayBispecific AntibodiesBiteCD3 AntigensCTLA4 geneCancer CenterCancer PatientCarbohydratesCell Surface ProteinsCell surfaceCellsClinical TrialsCombined Modality TherapyComplexDataDetectionDevelopmentDiseaseDisease ProgressionDoseDrug KineticsFDA approvedFc domainFundingFutureHalf-LifeHumanImmuneImmune checkpoint inhibitorImmune systemImmunoglobulin FragmentsImmunosuppressive AgentsImmunotherapeutic agentImmunotherapyIn VitroIntravenous infusion proceduresInvadedInvestigational TherapiesLectinMalignant NeoplasmsMetastatic/RecurrentNational Cancer InstituteNational Cancer ProgramNeoplasm MetastasisNormal CellNormal tissue morphologyPatientsPhasePhase I Clinical TrialsPhosphatidylinositolsPhosphotransferasesPolysaccharidesPrognosisProteinsReceptor Protein-Tyrosine KinasesRefractoryRegulatory T-LymphocyteRelapseSafetySequential TreatmentSerumSignal PathwaySignal TransductionSolidSolid NeoplasmSpecificitySurfaceSurface AntigensT-Cell ActivationT-Cell ReceptorT-LymphocyteTechnologyTestingTherapeuticTimeToxic effectTransgenic MiceTumor AntigensWorkbi-specific T cell engagercancer cellcancer immunotherapycell motilitycostdriver mutationfirst-in-humanhumanized mouseimmune checkpoint blockadein vitro activityin vivomanufacturemouse modelneonatal Fc receptorneonatal humannew technologynovelnovel therapeuticsoverexpressionpalliativephase I trialpre-clinicalpreclinical developmentpreventprogrammed cell death protein 1programssafety assessmentstable cell linesugartumor growth
项目摘要
Abstract
Treatment of non-resectable recurrent/metastatic solid cancers is currently palliative only and there is an
urgent unmet need for novel mechanisms of action and additional paradigm shifting therapeutic options. Antigen-
targeting cancer immunotherapies such as bi-specific antibodies (eg Bi-specific T cell engager or BiTE’s) provide
a unique approach for cancer immunotherapy. However, applying this therapeutic tactic to solid cancers has
been restricted by a limited number of protein antigens safe for targeting. Moreover, even if safe cell-surface
antigens are identified, different bi-specific antibodies will likely be needed for each different antigen/cancer. This
would greatly increase development time and costs. Thus, there remains a great need for additional safe antigen-
specific immunotherapies, particularly for those with refractory/metastatic solid cancers who have few
therapeutic options. Many cell surface cancer-specific antigens are not proteins but rather complex
carbohydrates that have limited or no expression in normal tissues. For example, β1,6GlcNAc-branched N-
glycans constitute a small subset of the complex-type N-glycans expressed at the surface of normal human cells
but are markedly up-regulated in diverse solid cancers by driver mutations in the receptor tyrosine
kinase/RAS/phosphoinositide-3-kinase(PI3K) signaling pathway. Aberrant over-expression of β1,6GlcNAc-
branched N-glycans in solid tumors drives RTK signaling, tumor growth, motility, invasion, and metastasis. As
both a marker and driver of many diverse cancers, β1,6 GlcNAc-branched N-glycans provide an excellent target
for antigen-specific immunotherapies. However, an antibody to β1,6GlcNAc-branched N-glycans has never been
generated. To address this issue, we generated a novel class of immunotherapeutics that readily target abnormal
glycan antigens with high specificity. We have termed this technology ‘Glycan-dependent T cell Recruiter’
(GlyTR, pronounced ‘glitter’). With funding from the Biden Cancer Moonshot program of the National Cancer
Institute, we developed and optimized the GlyTR1 bi-specific protein that binds both β1,6GlcNAc-branched N-
glycans and CD3 in T cells. The GlyTR1 bi-specific protein induces T cell-dependent killing of a wide diversity of
solid cancers in vitro and in vivo with EC50’s as low as ~50 femtomolar, yet does not kill normal cells or trigger
“on-target, off-cancer” toxicity in humanized mouse models. GlyTR1 is undergoing late-stage IND-enabling
studies and upon FDA approval, the UC Irvine Cancer Center will perform a dose-escalation Phase 1 clinical
trial in relapsed/metastatic solid cancer. However, as GlyTR1 has a short half-life of ~2.5hrs and requires
constant intravenous infusion, herein we propose to develop a longer half-life version of GlyTR1. We also
propose to examine for potential additive/synergistic activity with checkpoint inhibitors. Data from this
proposal will be used to inform future clinical trials following confirmation of safety of GlyTR1 in our Phase 1 trial,
namely whether a longer half-life GlyTR1 and/or co-treatment with checkpoint inhibitors should be pursued.
摘要
不可切除的复发/转移性实体癌的治疗目前只是姑息性的,有一种
对新的作用机制和更多范式转换治疗选择的迫切需求尚未得到满足。抗原-
靶向癌症免疫疗法,如双特异性抗体(如双特异性T细胞结合蛋白或BITE)提供了
一种独特的癌症免疫治疗方法。然而,将这一治疗策略应用于实体癌症
受到可安全靶向的有限数量的蛋白质抗原的限制。此外,即使安全的细胞表面
识别抗原后,每个不同的抗原/癌症可能需要不同的双特异性抗体。这
将大大增加开发时间和成本。因此,仍然非常需要额外的安全抗原-
特异性免疫疗法,特别是对那些难治性/转移性实体癌患者,他们几乎没有
治疗选择。许多细胞表面癌特异性抗原不是蛋白质,而是复杂的
在正常组织中有限表达或不表达的碳水化合物。例如,β-1,6GlcNAc-分支的N-
多聚糖构成了在正常人细胞表面表达的复合型N-多聚糖的一小部分
但在不同的实体肿瘤中,受体酪氨酸的驱动突变显著上调
激酶/RAS/磷脂酰肌醇-3-激酶(PI3K)信号通路。β-1,6GlcNAc-的异常过表达
实体肿瘤中的分枝N-糖链驱动RTK信号转导、肿瘤生长、运动、侵袭和转移。AS
β-1,6-GlcNAc-分支N-糖链既是多种癌症的标志物,也是多种癌症的驱动因素,是一个极好的靶点
用于抗原特异性免疫疗法。然而,针对β-1,6GlcNAc-支链N-糖链的抗体从未出现过
已生成。为了解决这个问题,我们产生了一种新的免疫疗法,可以很容易地针对异常
具有高度特异性的糖链抗原。我们将这项技术命名为“依赖多糖的T细胞招募器”
(Glytr,发音为“blitter”)。由拜登癌症登月计划资助的国家癌症
我们开发并优化了GlyTR1双特异性蛋白,它能结合β1,6GlcNAc分支的N-
T细胞中的糖链和CD3。GlyTR1双特异性蛋白诱导T细胞依赖的杀伤
S在体内外对实体瘤的EC50值低至~50毫微克分子,但不杀死正常细胞或触发
在人源化小鼠模型中的“靶标上,癌症外”毒性。GlyTR1正在进行后期IND启用
研究和FDA批准后,加州大学欧文癌症中心将进行剂量递增第一阶段临床
复发/转移性实体癌试验。然而,由于GlyTR1的半衰期很短,约为2.5小时,需要
在此,我们建议开发一种半衰期更长的GlyTR1版本。我们也
建议检查检查点抑制剂的潜在添加/协同活性。来自于此的数据
在我们的第一阶段试验中,GlyTR1的安全性得到确认后,该提案将用于通知未来的临床试验,
也就是说,是否应该寻求更长的半衰期GlyTR1和/或与检查点抑制剂联合治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL DEMETRIOU其他文献
MICHAEL DEMETRIOU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL DEMETRIOU', 18)}}的其他基金
Regulation of B cell function in demyelinating disease by N-glycan branching
N-聚糖分支调节脱髓鞘疾病中的 B 细胞功能
- 批准号:
10311524 - 财政年份:2019
- 资助金额:
$ 40万 - 项目类别:
Regulation of B cell function in demyelinating disease by N-glycan branching
N-聚糖分支调节脱髓鞘疾病中的 B 细胞功能
- 批准号:
10535482 - 财政年份:2019
- 资助金额:
$ 40万 - 项目类别:
Mechanisms of human immune modulation by oral N-acetylglucosamine
口服N-乙酰氨基葡萄糖调节人体免疫的机制
- 批准号:
9272357 - 财政年份:2014
- 资助金额:
$ 40万 - 项目类别:
Mechanisms of human immune modulation by oral N-acetylglucosamine
口服N-乙酰氨基葡萄糖调节人体免疫的机制
- 批准号:
8851521 - 财政年份:2014
- 资助金额:
$ 40万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 40万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 40万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 40万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 40万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别: